For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a platelet P2Y₁₂ receptor inhibitor, has been the gold standard of antithrombotic pharmacology after percutaneous coronary intervention (PCI). In the past 5 years, several investigations have challenged this paradigm by testing the efficacy and safety of P2Y₁₂ inhibitor monotherapy (that is, without aspirin) following a short course of DAPT. Collectively, these studies suggested a reduction in the risk of major bleeding and no significant increase in thrombotic or ischaemic events compared with guideline-recommended DAPT. Current recommendations are evolving to inform clinical practice on the ideal candidates for P2Y₁₂ inhibitor monotherapy after PCI. Generalizing the results of studies of P2Y₁₂ inhibitor monotherapy requires a thorough understanding of their design, populations, interventions, comparators and results. In this Review, we provide an up-to-date overview on the use of P2Y₁₂ inhibitor monotherapy after PCI, including supporting pharmacodynamic and clinical evidence, practical recommendations and future directions.

_{20 年来，由阿司匹林和血小板 P2Y 12}受体抑制剂联合组成的双重抗血小板疗法 (DAPT)一直是经皮冠状动脉介入治疗 (PCI) 后抗血栓药理学的金标准。在过去的 5 年中，一些研究通过测试短期 DAPT 后P2Y ₁₂抑制剂单一疗法（即没有阿司匹林）的疗效和安全性来挑战这种范式。总的来说，这些研究表明，与指南推荐的 DAPT 相比，大出血风险降低，血栓或缺血事件没有显着增加。_{目前的建议正在不断发展，以告知临床实践 P2Y 12}的理想候选人PCI 后抑制剂单药治疗。_{概括 P2Y 12}抑制剂单一疗法的研究结果需要透彻了解它们的设计、人群、干预措施、对照药和结果。在这篇综述中，我们提供了PCI 后使用 P2Y ₁₂抑制剂单一疗法的最新概述，包括支持药效学和临床证据、实用建议和未来方向。